Industry Insights

  1. Strategic ADC Development In A Shifting Regulatory Landscape 8/28/2026

    As ADC development grows more complex, sponsors must align safety, dose optimization, global trial design, regulatory strategy and CMC readiness early to reduce risk and accelerate approval.

  2. The Pharmacy Benefit No One Is Managing: Clinical Research As A Care Option 8/28/2026

    Pharmacies could make trials more accessible — if they preserve patient trust while research partners handle the operational burden.

  3. AI in Clinical Trials: 5 Practical TrialKit Use Cases for Data Management 8/27/2026

    AI is improving daily data management with automation, faster issue detection, and smarter reviews. This piece outlines practical use cases and what teams need to enable real, sustainable adoption.

  4. From Data Capture To Clinical Intelligence: How AI Is Expanding EDC In Clinical Trials 8/27/2026

    Modern electronic data capture (EDC) systems are transforming clinical trials by evolving from data repositories into dynamic clinical intelligence hubs.

  5. Proving CNS Target Engagement With Neuroimaging In Early Clinical Drug Development 8/27/2026

    The key question is not whether a scan changes, but what link in the dose-to-effect chain it resolves. Combining PET, MRI, PK/PD, and functional measures reduces uncertainty.

  6. Planning A Global Clinical Trial With The Right Sites, Not The Most Sites 8/27/2026

    Less is more for Yi Larson and the team at Excursion Therapeutics, which opted to build right site network — not the largest one — for its Phase 2 trial.

  7. Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections 8/27/2026

    Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.

  8. It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials 8/26/2026

    Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

  9. Turning A Historically Limited Modality Into A Respiratory Drug Opportunity 8/26/2026

    How can sponsors revive a promising modality with known safety limits? Vast Therapeutics CEO Nate Stasko, Ph.D., explains how ALX1 is reshaping nitric oxide delivery.

  10. The Rise Of Chinese Biotechs And The Global CRO Question 8/25/2026

    As innovative therapies move beyond home markets, early planning across regulators and geographies helps avoid costly delays and protect trial budgets.